On the first trading day after the Spring Festival, the trading limit of quadruple bull stocks Aba Chemicals Corporation(300261) before the festival was resumed after the suspension verification.
Some investors analyzed that ” Aba Chemicals Corporation(300261) fell sharply because of the high rise in the early stage and the demand to make up for the decline; secondly, the company clarified some facts and the market returned to rationality.”
The previous night, Aba Chemicals Corporation(300261) disclosed that due to the recent abnormal fluctuation of the company’s share price, the trading of the company has been suspended since January 17. During the suspension, the matters related to the abnormal fluctuation of stock trading have been verified. At present, the verification has been completed. Upon application, the trading has been resumed since the opening of the market on February 7.
According to the data, Aba Chemicals Corporation(300261) main business includes pesticide intermediates, pharmaceutical intermediates, environmental protection products, etc.
However, since last November, Aba Chemicals Corporation(300261) has been stained with the “Pfizer concept”, the company’s share price has risen from a maximum of 5 yuan to a high of 27.32 yuan, up more than four times.
Previously, the company mentioned that “carbonic anhydride and its derivatives can be used to synthesize Pfizer covid-19 oral drug parovid from the process flow”. This makes the outside world think that Aba Chemicals Corporation(300261) has business relations with Pfizer.
The sharp fluctuation of stock price has attracted the intervention of regulators. in the reply of many attention letters, Aba Chemicals Corporation(300261) clarified that the company has no cooperation with Pfizer, has not signed a cooperation agreement with Pfizer, and has not supplied carlon anhydride products to Pfizer.
But investors in the secondary market “turn a deaf ear”.
From November 1, 2021 to January 28, 2022, the company’s stock price increased by about 432.55%, which was significantly higher than the change degree of the company’s fundamentals and did not match the company’s current fundamentals. Since November 1, 2021, the rising range of the company’s stock price and the level of dynamic P / E ratio have been significantly higher than the industry average.
In the latest announcement, Aba Chemicals Corporation(300261) once again stated that “carbonic anhydride and its derivatives can be used to synthesize Pfizer covid-19 oral drug palovide” in the process flow stated in the reply to the concern letter disclosed by the company on January 5, 2022, in which carbonic anhydride and its derivatives refer to compounds rather than products produced by the company, It cannot be determined that the carbonic anhydride and its derivatives produced by the company can be used to synthesize Pfizer covid-19 oral drug. The company has no business contact and cooperation with Pfizer, has not signed a cooperation agreement with Pfizer, has not supplied Carlin anhydride products to Pfizer, Pfizer has not provided the company with any quality standards for the procurement of covid-19 oral drug front-end raw materials, and the company’s customers refuse to provide the end use of Carlin anhydride and its derivatives, The company is unable to determine whether the produced carbonic anhydride products meet the needs of Pfizer products, and has not conducted relevant technical verification. It is unable to determine whether the carbonic anhydride products produced by the company are or can become Pfizer covid-19 oral drug intermediates.
Although compared with the dynamic P / E ratio, range rise and fall and average value of Listed Companies in the same industry, the company’s range share price is unparalleled; However, compared with the ups and downs of the stock price, Aba Chemicals Corporation(300261) has a much flat performance. The growth rate of the company’s expected performance in 2021 is not high.
Aba Chemicals Corporation(300261) it is estimated that the net profit attributable to the parent company in 2021 will be 180 million yuan to 200 million yuan, an increase of 11.79% to 24.21% over the same period of the previous year, and the net profit after deducting non recurring profits and losses will be 142 million yuan to 162 million yuan, an increase of – 1.54% to 12.33% over the same period of the previous year.
Among them, the sales revenue of carbonic anhydride and its derivatives is 27.073 million yuan (excluding tax), accounting for about 1% – 2% of the company’s total operating revenue in 2021. As of December 31, 2021, the total amount of orders on hand for carbonic anhydride and its derivatives was only 63.5408 million yuan (excluding tax).
In response to the previous announcement that “the company is studying and planning the capacity expansion of carlon anhydride and its derivatives”, the company has also changed its oral statement, “the company learned that other manufacturers in the industry plan to invest in the construction of the production line of carlon anhydride and its derivatives, and the design capacity is much higher than the company’s existing capacity.” “After the large-scale production of other manufacturers, the production cost is expected to be lower than the production cost of the company’s products, which may lead to the risk of loss of orders, reduction of revenue, decline of profitability and so on.” “At present, the company has not decided whether to expand production, and there is still great uncertainty about whether to expand production in the end.”
At the end of last year, the market hyped a round of covid-19 drug concept stocks, and as the boom subsided, there was a wave of significant adjustment, such as Jiangxi Fushine Pharmaceutical Co.Ltd(300497) and senxuan medicine.
Aba Chemicals Corporation(300261) has also been suspended for verification twice before. From December 29, 2021 to January 5, 2022, the trading of the company’s shares was suspended for verification due to changes. After the resumption of trading on January 6, 2022, the company’s share price fell briefly, but rose more than 80% in the following five trading days until the second suspension verification.
Interestingly, Aba Chemicals Corporation(300261) once replied to the letter of concern of Shenzhen stock exchange that “there is no motivation to rub covid-19 drug hot spots”.
